Department of Dermatology, Sydney Cancer Centre, University of Sydney, Sydney, New South Wales, Australia.
Australas J Dermatol. 2009 Nov;50(4):266-71. doi: 10.1111/j.1440-0960.2009.00556.x.
Topical immunotherapy with contact sensitizers for metastatic melanoma was first reported more than 30 years ago. Diphencyprone (DPCP) immunotherapy is frequently used to treat cutaneous warts and alopecia areata, and we have previously reported the use of DPCP as a single agent to successfully treat extensive, radiotherapy-resistant melanoma metastases on the scalp. We now report DPCP treatment of a further six patients with cutaneous metastatic melanoma. Of seven patients treated with DPCP thus far, four have demonstrated complete responses of their cutaneous lesions and three have had partial responses. The treatment was well-tolerated by all patients. Topical immunotherapy with DPCP is inexpensive and relatively non-invasive and should be considered in patients with locally advanced skin metastases that are unsuitable for other therapies.
三十多年前首次报道了用接触致敏剂进行转移性黑素瘤的局部免疫治疗。二氯苯丙二酮（DPCP）免疫疗法常用于治疗皮肤疣和斑秃，我们之前曾报道过使用 DPCP 作为单一药物成功治疗头皮上广泛的、放疗抵抗的黑素瘤转移。我们现在报告了 DPCP 治疗另外六例皮肤转移性黑素瘤患者的情况。迄今为止，在接受 DPCP 治疗的七名患者中，四名患者的皮肤病变完全缓解，三名患者部分缓解。所有患者均耐受良好。DPCP 的局部免疫治疗费用低廉且相对无创，对于不适合其他治疗的局部晚期皮肤转移患者应考虑使用。
